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ABSTRACT
PREDICTORS OF ANEMIA AMONG HIV PATIENTS IN UGANDA
MAY 2017
CATHERINE S. NAGAWA, B.S., MAKERERE UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Marquis Hawkins
HIV-related anemia is associated with increased risk of death. Prior studies suggest
an inverse relationship between CD4 cell count and anemia, and a positive relationship
between HIV-clinical stage and anemia. However, none have assessed the role of
antiretroviral therapy (ART) treatment combinations in these relationships. Therefore, we
conducted a cross-sectional study to evaluate the relationship between CD4 cell count, HIV
clinical stage and anemia among 4803 Ugandan HIV-patients, and assessed the role of
ART treatment combinations. We included HIV patients (> 15 years) receiving ART
therapy combinations between 2010- 2015. We evaluated CD4 cell count and anemia using
blood tests, and HIV-clinical staging was based upon the World Health Organization HIVclinical staging system. Information on ART treatment combinations was obtained from
patients’ medical records. Multinomial logistic regression was used to model the
relationship between CD4 cell count, HIV clinical stages and anemia. We performed a
sensitivity analysis to examine the role of ART treatment combinations. The odds of being
severely anemic were highest among those classified in the low CD4 cell count category
(<200cells/µL), and those at WHO stage IV. Odds Ratios were 3.7 (95% CI; 1.48-9.26)
and 3.2 (95% CI; 1.75-5.70), respectively. Stratification by ART treatment combinations
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(TDF-based versus ADZ-based combination treatment) indicated an increase in the odds
of being anemic with increase in HIV-clinical stage (stage II, OR: 1.99, 95% CI; 1.44-2.78;
stage III, OR:3.17, 95% CI; 2.21-4.54, & stage IV, OR; 4.42, 95% CI; 2.68-7.30), for
individuals receiving TDF-based treatment only. Results suggest that HIV-patients with a
low CD4 cell count and, those in advanced HIV-clinical stages should consider regular
hemoglobin follow-up to identify and treat anemia at its earliest stages.
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CHAPTER 1
INTRODUCTION
A. Human Immunodeficiency Virus
The Human Immunodeficiency Virus (HIV) destroys CD4 cells, gradually
damaging the immune system.1 CD4 cells are a type of white blood cells that signal
activation of the body’s immune response upon virus detection. A higher CD4 cell count
is indicative of a strong immune system.2 Without treatment, HIV–infected individuals
typically progress through four

clinical stages of infection, namely; primary HIV-

infection; clinically asymptomatic stage; symptomatic HIV infection; and Acquired
Immunodeficiency Syndrome (AIDS).3 These stages are typically referred to as HIV
clinical stages I, II, III and IV.
HIV clinical stage I. Primary HIV Infection (HIV clinical stage I) lasts a few
months after infection and is often characterized with presence of Persistent Generalized
Lymphadenopathy (PGL), that is, the enlargement of lymph nodes, in at least 2 body sites
for a period of 6 months. During this stage, there is a large amount of HIV in the peripheral
blood and the immune system initiates production of HIV antibodies.
HIV clinical stage II. Clinical asymptomatic stage (HIV clinical stage II) lasts for
an average of ten years, and is devoid of major symptoms; however, HIV is active in the
lymph nodes.
HIV clinical stage III. HIV clinical stage III is also known as the symptomatic HIV
Infection stage, and results from mild damage to the immune system marked by presence
of HIV- related bacterial infections such as pneumonia. HIV clinical stage III develops due
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to; 1) damaged lymph nodes; 2) increased CD4 cell destruction; and 3) failure of the
immune system to replace destroyed CD4 cells.
HIV clinical stage IV. HIV clinical stage IV is often referred to as AIDS, and results
from severe damage to the immune system. At present, confirmation of AIDS diagnosis
occurs when an HIV infected individual develops one or more HIV-related opportunistic
infections such as cryptococci meningitis and HIV- related cancers such as Kaposi’s
sarcoma.
Prevalence of HIV in Uganda
In 2015, an estimated 1.5 million Ugandans were living with HIV. HIV prevalence
among adults, aged 15 to 49, was estimated to be 7.1% (6.6% - 7.7%). The number of
deaths due to AIDS was estimated to be 28,000 individuals.
The number of new HIV infection cases increased by 21% between 2005 and
2013.4 However, there was an observed decrease of new cases between 2013 and 2015.
Specifically, the number of new HIV infection cases reduced from 140,000 in 2013 to
83,000 in 2015.5 The reduction in new infections has been attributed to the increased use
of antiretroviral therapy (ART) treatments.6 ART refers to combinations of antiretroviral
drugs that suppress HIV viral replication and prevent progression of the disease.
B. HIV- related Anemia
Anemia is a condition that occurs when hemoglobin levels in a person’s blood drop
below normal. Hemoglobin is a protein molecule in the red blood cells that carries oxygen
throughout the body.7 Normal hemoglobin levels are defined as 13 grams (g) or higher per
deciliter (dL) of blood.8 The decrease in hemoglobin levels is due to body conditions that
negatively influence the number of red blood cells present in the body. In HIV-patients,
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conditions that are likely to influence red blood cell quantity are amount of CD4 cell count
and the level of HIV clinical stage (presence or absence of HIV-related clinical
manifestations).9
Prevalence of Anemia in HIV- infected individuals in Uganda
In different clinical settings, the prevalence of HIV- related anemia among HIVinfected individuals receiving ART varies greatly.11 Prevalence rates range from 65% to
95% in sub-Saharan Africa12–14 and 20% to 60% in developed countries.10,15 This is due to
differences in the prevalence of anemia risk factors; such as endemic malnutrition,
helminthes infections and a different spectrum of opportunistic infections.11
Established Risk Factors. Known HIV-related anemia risk factors include gender
and type of ART medication Women, as compared to men, are more likely to develop
anemia due to blood loss during menstruation, pregnancy and delivery.17–19 Anemia in
HIV-infected individuals also results from the direct effect of antiretroviral agents,
particularly zidovudine, on the hematopoietic process in the body.20 Hematopoietic is the
process through which blood or blood cells are formed in the body.
Sequelae of HIV-related Anemia. Anemia diagnosis in HIV-infected individuals
has been associated with reduced quality of life,21 quick progression of HIV,14,22 decreased
survival time,23 and increased risk for death.15
C. Epidemiological Background
Recent literature suggests an association between CD4 cell count, HIV- clinical
stage and HIV –related anemia.

24–27

In particular, epidemiological research suggests a

inverse association between CD4 cell count and anemia,
between HIV- clinical stages and anemia.
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24–27

and a positive association

Epidemiology of the association between CD4 cell count and anemia
Between 2009 and 2016, three studies examined the relationship between CD4 cell
count and HIV-related anemia in low–resource settings.25–28 All three studies were crosssectional; of these, two were single site clinic studies performed in Tanzania25 and India26.
The third study was conducted in rural China28 using national data.
Study findings indicate that individuals with low CD4 cell count have increased
odds of being anemic. Odds ratios were 2.27 with 95% confidence Interval (CI) 1.33 –
3.88), for study participants in Tanzania, 1.21 (95% CI; 1.07 – 1.3) for China and 5.0 (95%
CI; 4.0 – 6.3) for Ethiopia.
Although all three study findings indicate an inverse association between CD4 cell
count and HIV-related anemia, none of the studies controlled for ART treatment in the
analysis. Combination ART treatment has been found to be positively associated with CD4
cell count and inversely associated with anemia.29,30 Failure to adjust for combination ART
treatment may have underestimated the association between CD4 cell count and anemia.
Epidemiology of the association between HIV-clinical stage and anemia
One of the three studies described above assessed HIV-clinical stage as an exposure.
This study was conducted in Tanzania,

25

and compared HIV-clinical stage classified into

two categories (HIV clinical stage I and II versus HIV-clinical stage III and IV).
Findings show that individuals classified in HIV-clinical stage III and HIV clinical
stage IV were more likely to be anemic compared to those classified at HIV-clinical stage II
and HIV-clinical stage I. Odds Ratios were 5.3 (95% CI; 3.15 – 8.9).
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However, the relationship between HIV-clinical staging and anemia was not adjusted
for ART treatment. Because ART treatment is positively associated with HIV-clinical stage
and negatively associated with anemia, it is likely that this association was underestimated.
Therefore, we conducted a cross-sectional study among Ugandan HIV-infected
adults (N = 4803) to examine the relationship between CD4 cell count, HIV-clinical stage,
and anemia and adjusting for ART treatment.
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CHAPTER 2
STUDY DESIGN AND METHODS
A. Study Design
We used a cross-sectional design to examined the association between CD4 cell
count, HIV- clinical stage and anemia among HIV patients in Uganda. Data were
electronically captured by the Ministry of Health national surveillance system between
2010 and 2015. The Ministry of Health developed the system in 2010. The aim of the
system is to promote the use of locally generated health data to facilitate evidence-based
decision making on planning and resource allocation within the country’s healthcare sector.
B. Study Population
The study population comprised of 5276 HIV patients older than 15 years who
received ART between 2010 and 2015 at three regional referral hospitals (RRH): 1) Hoima
RRH in mid-western Uganda; 2) Fort-Portal RRH in western Uganda; and 3) Mubende
RRH in central Uganda.
Eligibility
We excluded 1) those younger than 15 years of age (n= 287), and 2) women who
were pregnant (n = 186). The final sample number used in the analysis is 4803 (Figure 1).
Pregnant women were excluded from the study due to differences in physiological
mechanisms29 and clinical definitions of anemia.

6

C. Study Methods
Assessment of CD4 cell count
We assessed CD4 cell count as a categorical variable. Categories for CD4 cell count
were: Low (˂ 200 cells per microliter (cells/µL); Moderate (200 - ≤ 500 cells/µL); and
High (˃ 500 cells/µL).
Laboratory Procedure. To obtain CD4 cell counts, we performed complete blood count
tests at the central public health laboratory located at Makerere University. Blood was
drawn using venipuncture and kept at ambient temperatures. The laboratory center used
tritest reagents to determine CD4 cell count.
Assessment of HIV Clinical Stage
HIV clinical staging was based upon the World Health Organization (WHO)
clinical staging system. The WHO clinical staging system is widely used in resourcelimited countries, particularly in the sub-Saharan African Region. 30,

31

To accommodate

facilities with no or limited access to laboratory, the WHO HIV clinical staging system
established standardized clinical guidelines for direct medical decision making, based on
the patient’s clinical manifestations.
Individuals are classified in WHO stage I if they have Persistent Generalized
Lymphadenopathy PGL in at least two sites of the body for longer than 6 months.
HIV infected individuals are classified into WHO Stage II when clinical outcomes
include: 1) unexplained weight loss of less than 10 percent of total body weight; 2)
recurrent respiratory infections (such as sinusitis, bronchitis, otitis media, and pharyngitis),
and 3) range of dermatological conditions including herpes zoster flares, angular cheilitis,
and recurrent oral ulcerations.
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WHO stage III signs and symptoms include: 1) weight loss of greater than 10
percent of total body weight; 2) prolonged (more than 1 month) unexplained diarrhea; 3)
pulmonary tuberculosis; and 4) severe systemic bacterial infections including pyomyositis,
meningitis, bone and joint infections, and bacteremia.
WHO stage IV includes all of the above illnesses, and presence of HIV wasting
syndrome, Pneumocystis pneumonia (PCP), recurrent severe or radiological bacterial
pneumonia, extra-pulmonary tuberculosis, HIV encephalopathy, CNS toxoplasmosis,
chronic herpes simplex infection, esophageal candidiasis, and kaposi’s sarcoma. Other
diagnostic conditions include cytomegalovirus infections, extra pulmonary cryptococcosis,
disseminated non-tuberculous mycobacteria infection, tracheal, bronchial or pulmonary
candida infection etc.
In this study categories for HIV clinical stages were defined as WHO stage I, WHO
stage II, WHO stage III and IV.
Assessment of Anemia
We assessed anemia using blood hemoglobin levels according to WHO hemoglobin
cut-off points. Per WHO guidelines, non-anemic patients were described as those with >
12 g/dl for non-pregnant women and >13 g/dl for men. Anemia severity was categorized
as mild anemia (10 - < 13/12 g/dL), moderate anemia (8 - < 10 g/dL), and severe anemia (
< 8 g/dL) for both sexes.8
Laboratory Procedures. All patients participated in a standardized laboratory assessment
consisting of hematological tests. Hematological indices including, hemoglobin
concentration, and red blood cell indices (mean corpuscular volume and mean corpuscular
hemoglobin), were determined using an automated hematology analyzer - COULTER®
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Ac·T™ 5diff CP (Cap Pierce). We categorized hemoglobin concentration according to
WHO criteria.
Covariates.
We collected data on age, gender, ART, presence or absence of tuberculosis, and
duration on ART medication from the system. Covariates were selected based on inclusion
in prior literature 24–27 and their potential for confounding as demonstrated in previous
findings.
Statistical Analysis
Using cross-tabulation, we assessed the unadjusted relationship between CD4 cell
count and anemia, and HIV-clinical stage and anemia. We used chi-square tests to calculate
p-values for categorical variables, and ANOVA for continuous variables. We used
multinomial logistic regression to model the relationship between CD4 cell count, HIV–
clinical stages and anemia. We used a change-in-estimate approach to evaluate
confounding. Potential confounders included age, gender, length and type of ART
treatment, and Tuberculosis status. Covariates that caused a 10% change in coefficients for
either CD4 cell count or HIV-clinical stage were adjusted for in the final model.
Stratification Analysis. We assessed anemia dichotomously (anemic vs nonanemic) and stratified study participants based on type of ART treatment received, those
with missing data on type of ART treatment were excluded. Therefore, study participants
were classified as receiving either a AZT- or TDF- based treatment combination (n = 4457).
We calculated adjusted odds ratios (OR) and 95% confidence intervals to determine the
strength of associations between the CD4 cell count, HIV clinical stage and anemia.
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CHAPTER 3
RESULTS
Characteristics of the Study Population.
A total of 4803 HIV positive individuals (1668 males and 3135 females), receiving
ART treatment therapy combinations between 2010-2015, were used to examine the
relationship between CD4 cell count, HIV clinical stage and anemia. The mean age and
standard deviation (mean ± S.D) of the study participants was 38.9 ± 10.5 years, with a
range of 15 to 94 years. The median CD4 count was 220.0 cells/µL (IQR: 27 – 295). Thirtyfour percent of the study participants were classified at WHO stage 1, 36% at WHO stage
II, 24% WHO stage III, and 6.1% as WHO stage IV. Approximately 68% of the study
participants reported receiving HIV treatment for a duration of 3 years or less, only 3%
reported tuberculosis medication use. Sixty percent of the study participants were using
AZT-based treatment combination (Table 2).
Prevalence of Anemia
Anemia was present in 28.8% of the study participants. Prevalence of mild,
moderate and severe anemia were 20.6%, 4.5% and 3.7%, respectively. Gender was
significantly associated with anemia (P-value < 0.001) with gender-specific prevalence
rates of 30% (female) and 23.2% (males). CD4 cell count significantly decreased with
increase in anemia severity levels (P- value < 0.001); that is, the mean ± SD CD4 cell count
for study participants with no anemia, mild, moderate and severe anemia were 236.6 ±
210.2, 194.2 ± 145, 143.1 ± 135.2 and 147.1 ± 142.2, respectively. Prevalence of anemia
differed significantly by WHO clinical stage; for example, study participants with mild
anemia comprised of 30% of individuals categorized at WHO stage 1, 42% at WHO stage
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II, 23% at WHO clinical stage III, and 5.6% at WHO clinical stage IV. Within the severe
anemia category, about 18% were at WHO stage I, 30% at WHO stage II, 39% at WHO
stage III & 13% at WHO stage IV (Table 2).
ART treatment type was significantly associated with anemia. Almost half of the
study participants with severe anemia (48%) reported using a TDF-based treatment, and
62% of those categorized as having mild anemia reported using AZT-based treatment.
(Table 2)
The mean CD4 cell count decreased with increase in anemia severity; for instance,
individuals with no anemia had a mean CD4 cell count of 236.6 (201.2), and those with
mild anemia had a mean CD4 cell count of 194 (145). Anemia was most prevalent among
individuals at WHO stage II (Table 2).
CD4 cell count and Anemia
Mild anemia. Compared to individuals with high CD4 cell count, those with
moderate CD4 cell count (>200 - ≤ 500 cells/uL) were 94% more likely to be mildly anemic
(OR, 1.94, 95% CI: 1.28 - 2.93), and those with a low CD4 cell count had a 2-fold increase
in odds of being mildly anemic (OR, 3.12, 95% CI: 2.18 – 4.47) (Table 2).
Moderate anemia. Compared to study participants with high CD4 cell count, those with
moderate CD4 cell count had a 3-fold increase in odds of having moderate anemia (OR,
3.21, 95% CI: 1.60 – 3.65). Those with a low CD4 cell count had a 6-fold increase in odds
of having moderate anemia (OR, 6.10, 95% CI: 2.21 – 16.78).
Severe anemia. Compared to those with a high CD4 cell count, a moderate CD4 cell count
was insignificantly associated with increased odds of having severe anemia (OR: 1.92;
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95% CI: 0.752 – 4.89), and those with a low CD4 cell count had a 3-fold increase in odds
of having severe anemia (OR, 3.70, 95% CI: 1.48 – 9.26).
HIV clinical stages and Anemia
Mild anemia. Using study participants at WHO stage I as a reference group, those
at WHO clinical stage II were 29% (OR: 1.29, 95% CI: 1.08 – 1.54) more likely to have
mild anemia. WHO clinical stage III and IV were not statistically significantly associated
with having mild anemia, the odds ratios are 0.93 (95% CI: 0.76 – 1.16) and 1.22 (95% CI:
0.88 – 1.71) respectively.
Moderate anemia. Compared to study participants in WHO stage I, those at WHO clinical
stage 1I had increased odds of having moderate anemia (OR, 1.29, 95% CI: 0.94 – 2.07).
Those at WHO clinical stage III and WHO stage IV had a 2-fold increase of having
moderate anemia with odds ratios of 2.28 (95% CI: 1.53 – 3.38) and 2.16 (95% CI: 1.23 –
3.79), respectively.
Severe anemia. Compared to study participants in WHO stage I, those at WHO clinical
stage II were 62% more likely to have severe anemia (OR, 1.62, 95% CI: 1.03 – 2.55), and
those at WHO clinical stage III were at a 2-fold increase of having severe anemia (OR,
2.72, 95% CI: 1.73 – 4.29). Those at WHO clinical stage IV had a 3-fold increase of having
severe anemia (OR, 3.16, 95% 1.75 – 5.70).
We examined the joint effect of CD4 cell count and HV on anemia(yes/no) and
found that individuals with a lower CD4 cell count and at higher HIV clinical stages had
increased odds of having anemia compared to those with a high CD4 cell count and at
lower HIV-clinical stages (Figure 2).

12

Sensitivity Analysis
When we stratified the study participants per treatment received, we found that 64%
of the study participants were receiving AZT-based treatment, and had relatively lower
CD4 cell counts with a mean of 192 (138). On average, those receiving the AZT-based
treatment were older (40yrs. ± 10.4) than those receiving TDF-based treatment (36yrs.
± 10). Most of the study participants receiving TDF-based treatment were at HIV clinical
stage 1 (44%), while most of those receiving AZT-based treatment were at HIV clinical
stage II (Table 3).
Results from the stratified analysis indicate a statistically significant trend of
increasing anemia with increasing HIV clinical stage among individuals receiving TDFbased treatment only. Compared to those classified at WHO stage I, those at WHO stage
II were 99% more likely to be anemic (OR, 1.99; 95% CI: 1.44 – 2.77), those at WHO
stage III had a 3-fold increase of being anemic (OR, 3.17; 95% CI: 2.21 – 4.53), and those
at WHO stage IV had a 4-fold increase (OR; 4.42; 95% CI: 2.68 – 7.29) compared to those
receiving AZT-based regimen within the same stage.
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CHAPTER 4
DISCUSSION
A. Primary Findings
In this study population, prevalence of anemia was 28.8%. Females had a
significantly higher prevalence of anemia compared to males.
CD4 cell count. We found that HIV-infected patients with low CD4 cell count (< 200
cells/µl) had a significant increase in the odds of being anemic, compared to those with
high CD4 cell count (> 500 cells/µl).
HIV clinical staging. In comparison to the WHO stage 1, study results suggest that patients
at advanced HIV clinical stages (WHO stage IV) had increased odds of 1.22, 2.16 and 3.16
of having mild, moderate and severe anemia, respectively. This is in line with the study
research hypothesis.
Joint effect of the two exposures. When we examined the joint effect of CD4 cell
count and HIV clinical stage on anemia and found similar trends of the association. That
is, those with lower CD4 cell counts and at higher HIV clinical stages had increased odds
of having anemia compared to those with higher counts, at lower clinical stages.
The findings suggest that CD4 cell count may be predictive of early anemia onset
(mild or moderate anemia), and HIV clinical stages may be more predictive of severe
anemia. Additionally, study findings suggest that CD4 cell count is inversely associated
with anemia, and HIV clinical stages are positively associated with anemia, which is in line
with the research hypothesis.
Our study findings are consistent with results of Gunda et al. and Yin et al. who
reported that anemia was more prevalent among patients in the most advanced stages of
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HIV. And also, consistent with the results of Levine et al. and Volberding et al. who
reported that more severe levels of anemia are found among HIV- infected individuals
exhibiting low CD4 cell counts.
We found that for individuals receiving TDF-based treatment, the odds of being
anemic increased with an increase in HIV clinical stage. Absence of a similar association
among those receiving AZT-based treatment may be due to survivor bias. It is quite
possible that individuals receiving this treatment are deceased, and therefore were not
present to be selected for inclusion in the study. Possible explanations for increased risk
for death in the AZT-based treatment subgroup are; 1) AZT-based treatments are
recommended for women at childbearing age to prevent mother-to-child HIV transmission
and, 2) one of AZT’s known health side effects is anemia. Given that the female gender
and AZT are established risk factors for anemia, the observed findings may be explained
by differences in the characteristics of individuals receiving a particular treatment (AZT
versus TDF). Therefore, interpretation of the finding that there is an increase in the odds
of being anemic with increase in HIV clinical stage within the TDF-based treatment
subgroup only, should be precautious and further investigated prospectively.
To our knowledge, this is the first study to assess the relationship between CD4 cell
count, HIV clinical stage and anemia, and control for ART treatment combinations. This
approach provides more precise measures compared to those shown in prior research and
adds to the existing literature on the association between CD4 cell count, HIV clinical stage
and anemia among HIV –infected adults.
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B. Physiological Mechanisms
CD4 cell count. The physiologic association between CD4 cells and anemia among
HIV-infected individuals can be explained through two basic mechanisms; 1) reduced red
blood cell production, and 2) increased red blood cell destruction. First, CD4 cell
destruction caused by HIV infection leads to a disruption in the levels of natural chemicals
and normal functioning of the bone marrow, which in turn, reduces production of red blood
cells and therefore may lead to anemia. Secondly, CD4 cell destruction leads to a faulty
immune system where groups of disorders produce autoantibodies that attack the body’s
own red blood cells, thus increasing red blood cell destruction, which may lead to anemia.
HIV clinical staging. Blood loss and infection of the bone marrow may contribute
to the physiologic relation between HIV-clinical stage and anemia. Neoplastic diseases in
HIV infected individuals such as Kaposi’s sarcoma, atypical mycobacteria, Hodgkin’s
lymphoma and non-Hodgkin’s Lymphoma infect the bone marrow directly, or lead to
gastrointestinal blood loss that in turn reduces the number of red blood cells in the body
which may lead to anemia.
C. Study Strengths and Limitations
Non-Differential Misclassification of CD4 Cell Count
We obtained CD4 cell counts for all study participants using complete blood count
tests performed at the central public health laboratory at Makerere University. Complete
blood count test is standard for establishment of CD4 cell count.32 Therefore, nondifferential misclassification of CD4 cell count is unlikely to occur. If present, we would
expect an underestimation of the relationship between CD4 cell count and anemia with bias
towards the null.
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Non-Differential Misclassification of HIV-Clinical Stage
For this study, HIV–clinical staging is based upon WHO HIV-clinical staging
system. WHO HIV-clinical staging is widely used in low-resource settings.33,31 However,
the system relies on clinical manifestations of HIV, rather than laboratory confirmatory
tests. Therefore, non-differential misclassification of exposure (HIV clinical stage) is
highly likely. Bias due to non-differential misclassification will lead underestimation of
the true OR with bias towards the null.
Selection bias
Selection bias would occur if anemic patients with low CD4 cell count and those at
advanced stages of HIV were more likely to participate in the study. This would occur if
such patients were aware of the study hypothesis, and were more inclined to participate in
a study on this topic. Because participants were randomly selected from the ministry of
health surveillance system (eliminating any form of self-selection into the study), selection
bias is unlikely to occur.
Information Bias
Information bias could occur if one’s anemia status influenced collection of
information on exposure variables (CD4 cell count and HIV- clinical stage). It is highly
unlikely that information bias occurred in this study because data from all participants
(regardless of exposure status) was collected through routine medical visits, and captured
by the ministry of health surveillance system, from which it was extracted for this study.
Non-Differential Misclassification of Anemia
Hemoglobin levels were obtained through blood tests performed at the central
public health laboratory at Makerere University. Anemia definition was per WHO criteria
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for hemoglobin concentration in the blood. Although hemoglobin concentration in blood
is acceptable for anemia diagnosis,34 it is considered insufficient.35 More recently, it’s been
argued that evaluation of hemoglobin levels jointly with reticulocyte count, bilirubin and
mean corpuscular volume is better for anemia diagnosis.36 Therefore, non-differential
misclassification of anemia is possible, causing an underestimation of the study results with
a bias towards the null value. The magnitude of this effect may be moderate as hemoglobin
concentrations are generally accepted standard for anemia diagnosis for HIV-infected
individuals.35
Confounding
We did not have data on iron intake which is a potential confounder for the
relationship between CD4 cell count and anemia. Due to iron’s independent inverse
relationship with both CD4 cell count and anemia, bias due to confounding is likely and
may result into an overestimation of the study results. However, the impact of such bias on
the study results is expected to be minor because nutritional habits (the major source of
iron) may not vary greatly among individuals in this region.
Temporal sequence
Due to the cross-sectional nature of the study, information on the exposures (CD4
cell count and HIV–clinical stage) and outcome of interest (anemia) were collected at the
same point in time. Therefore, we cannot ascertain whether the exposures led to anemia,
or alternatively, if anemia influenced the exposures. This is particularly true for HIV
clinical stage. For example, it is more likely that patients were categorized into HIV clinical
stage III&IV because they exhibited anemia symptoms.
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On the contrary, it is unlikely that anemia would cause a reduction in CD4 cell
count considering the uniqueness of the study population (HIV-infected individuals). The
biological mechanism through which the HIV-virus operates in the body may describe a
causal pathway between CD4 cell and anemia. When the body is infected with HIV, the
virus directly destroys CD4 cells. CD4 cell destruction results into a fragile immune system
that adversely affects red blood cell count, likely leading to anemia.39 Therefore, among
HIV-infected individuals, it is highly unlikely that a low CD4 cell count may result from
anemic conditions, and because no prior literature suggests such an association, we expect
the impact of this bias to be minor.
For this cross-sectional study, a proper temporal sequence needed to ascertain
causality between HIV –clinical stage and anemia will not be firmly established.
Survivor Bias
Survivor bias would occur if HIV- patients with very low CD4 cell count were more
likely to die from severe anemic conditions, and therefore could not be included in the
study sample. Similarly, if those with high HIV-clinical stages III&IV were more likely to
die because of severe anemia. It is possible that our study results were underestimated due
to this bias. The odds ratio of severely anemic patients (OR: 3.7) is lower than that of
moderately anemic patients (OR: 6.10), this was not as expected and is likely due to
survivor bias.
D. Conclusion
In HIV- infected individuals, a low CD4 cell count and advanced clinical stages are
associated with anemia. Although our analyses cannot show whether this relationship is
causal, our findings are consistent with prior studies that have assessed this relationship.
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Consideration should be given to evaluating CD4 cell count, HIV clinical stage and anemia
in a prospectively to address the issue of issue of survivor bias. From a clinical standpoint,
the results suggest that patients with low CD4 cell count and those in advanced HIV clinical
stages, should have regular hemoglobin follow up to identify anemia at its earliest stages.
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Figure 1. Exclusion Criteria

Total number of HIV patients
(N = 5276)

Excluded
Younger than 15 years
(n = 287)
Adult HIV patients
(n = 4989)

Excluded
Pregnant women (n = 186)

Final sample
(n = 4803)
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Table 1. Distribution of covariates per Anemia status among Ugandan HIV patients 2010-2015
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Table 2. Adjusted Odds Ratios and 95% confidence intervals for CD4 cell count, HIV clinical stage, and Anemia in HIV
patients 2010-2015
Mild anemia vs No
Anemia
(n = 941)
OR
95% CI

Moderate anemia vs No
Anemia
(n = 215)
OR
95% CI

Severe anemia vs No
Anemia
(n = 176)
OR
95% CI

CD4 cell counts
High (> 500 cells/µL)
Moderate (200 - ≤ 500 cells/µL)
Low (< 200 cells/µL)
p-trend

37
510
785

1.00
1.94
2.41

referent
1.28 - 2.93
1.60 - 3.65
< 0.001

1.00
3.21
6.10

referent
1.15 - 8.93
2.22- 16.77
< 0.001

1.00
1.92
3.70

referent
0.75- 4.89
1.48 - 9.26
< 0.001

WHO HIV - clinical staging
WHO stage I
WHO stage II
WHO stage III
WHO stage IV
p-trend

365
516
349
102

1.00
1.29
0.93
1.22

referent
1.08 - 1.54
0.76 - 1.16
0.88 - 1.71
< 0.001

1.00
1.39
2.28
2.16

referent
0.94 - 2.07
1.53 - 3.38
1.23 - 3.79
< 0.001

1.00
1.62
2.72
3.16

referent
1.03 - 2.55
1.73 - 4.29
1.75 - 5.70
< 0.001

Model adjusted for age, gender and antiretroviral therapy combinations
Abbreviations: CI, Confidence Interval; WHO, World Health Organization
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Figure 2. Odds Ratios and 95% Confidence Intervals of the joint effect of CD4 cell count and Anemia (yes/no)
20.00
15.00
10.00
5.00
0.00
1
1

1

2

3

4

5

6

Figure
1.

High CD4 cell count and WHO Stage I (n = 163)

2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

High CD4 cell count and WHO Stage II (n =77)
High CD4 cell count and WHO Stage III (n = 46)
High CD4 cell count and WHO Stage IV (n = 16)
Moderate CD4 cell count and WHO Stage 1 (n = 947)
Moderate CD4 cell count and WHO Stage II (n = 751)
Moderate CD4 cell count and WHO Stage III (n = 311)
Moderate CD4 cell count and WHO Stage IV (n = 73)
low CD4 cell count and WHO Stage I (n =538)
low CD4 cell count and WHO Stage II (n = 899)
low CD4 cell count and WHO Stage III (n = 776)
low CD4 cell count and WHO Stage IV (n = 206)

Study participants were classified into 12 groups as shown above.
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8

9

10

11
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Table 3. Distribution of characteristics of study participants for each treatment
combination

Characteristics

TDF - based treatment

Number of study participants
Age mean (SD)
CD4 cell count mean (SD)
Duration on ART treatment (yrs.)
Gender (Female)
HIV clinical stage
WHO stage I
WHO stage II
WHO stage III
WHO stage IV
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AZT - based treatment

1589

2868

36.7 (10)

40.2 (10.4)

286 (246.9)

191.68 (137.7)

1.7 (0.8)

2.3 (1.02)

65%

64%

700 (44%)
484 (30%)
309 (19%)
96 (6%)

870 (30%)
1126 (40%)
709 (25%)
163 (9%)

Table 4. Odds Ratios and 95% Confidence Intervals for HIV clinical stage and Anemia
(yes/no) in HIV patients 2010-2015 stratified by ART treatment therapy.

AZT-based treatment (n = 2868)
WHO stage I
WHO stage II
WHO stage III
WHO stage IV
TDF - based treatment (n = 1589)
WHO stage I
WHO stage II
WHO stage III
WHO stage IV

non-cases

anemia cases

Adjusted*
OR
95% CI

614
747
498
113

256
379
211
50

1.00
1.23
1.04
1.09

referent
1.02 - 1.50
0.83 - 1.30
0.76 - 1.58

621
380
204
57

79
104
105
39

1.00
1.99
3.17
4.42

referent
1.44 - 2.78
2.21 - 4.54
2.68 - 7.30

Abbreviations: AZT, Azido-thymidine; TDF, Tenofovir disoproxil
*Adjusted for Gender and CD4 cell count
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